Imaging Efficacy of a Hepatocyte-Selective Polyiodinated Triglyceride (DHOG-LE) for Contrast–enhanced CT

Doerr-Stevens, Julie K.; Bakan, Douglas A.; Lee, Fred T.; Chosy, Susan G.; Markhardt, B. Keegan; Bonneville, Anne Killam; Burrascano, Cindy; Delaney, Cheryl; Longino, Marc A.; Greener, Yigal; Weichert, Jamey P.

doi:10.1016/s1076-6332(03)80436-1

Cited by 5 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 20% oil-in-water emulsion of glyceryl-2-oley-1,3-bis-[7-(3-amino-2,4,6-triiodophenyl)-heptanoate] (DHOG), corresponding to a polyiodinated triglyceride (ITG) analog incorporated in a neutral lipid core of chylomicron remnant-like lipid emulsion with particles of less than 200 nm in diameter, was shown to enable high-quality long-lasting visualization in micro-CT imaging studies, especially of the liver (8,(10)(11)(12)(13). Once sequestered by the liver, the triglyceride core is metabolized and excreted through the biliary system and taken up by the liver through a high-capacity receptor-mediated apolipoprotein-E process.…”

Section: Introductionmentioning

confidence: 99%

In‐vivo high‐resolution X‐ray microtomography for liver and spleen tumor assessment in mice

Almajdub

Nejjari

Poncet

et al. 2007

Contrast Media & Molecular

View full text Add to dashboard Cite

The present study sought to validate the use of glycery1-2-oley-1,3-bis-[7-(3-amino-2,4,6-triiodophenyl)- heptanoate] (DHOG) contrast agent for mouse spleen tumor and liver metastasis imaging by high-resolution X-ray microtomography. Three groups of female nude mice were compared: controls (n = 5), and mice injected with 2.5 x 10(6) STC1 tumor cells in the spleen, imaged at 15 days (group G15, n = 5) and at 30 days (group G30, n = 5, of which one died before imaging). Micro-CT scans (X-ray voltage, 50 kVp; anode current, 200 microA; exposure time, 632 ms; 180 rotational steps resulting in 35 microm isotropic spatial resolution) were acquired at 0, 0.75, 2 and 4 h after i.v. injection of DHOG. CT number (Hounsfield units: HU) and contrast-to-noise ratios (CNR) were determined in three organs. Statistical analysis was performed by Mann-Whitney U-test. Contrast enhancement in normal spleen and liver increased, respectively to 1020 +/- 159 and 351 +/- 27 HU over baseline at 4 h, and 482 +/- 3 and 203 +/- 14 HU on day 6 after a single contrast injection. Automated three-dimensional reconstruction and modeling of the spleen provided accurate and quantifiable images. Spleen tumor and liver metastases did not take up DHOG, making them detectable in contrast to the increased signal in normal tissue. The smallest liver metastasis detected measured 0.3 mm in diameter. High-resolution X-ray micro-CT in living mice using DHOG contrast agent allowed visualization and volume quantification of normal spleen and of spleen tumor and its liver metastases.

show abstract

Section: Introductionmentioning

confidence: 99%

In‐vivo high‐resolution X‐ray microtomography for liver and spleen tumor assessment in mice

Almajdub

Nejjari

Poncet

et al. 2007

Contrast Media & Molecular

View full text Add to dashboard Cite

show abstract

“…A recently developed hepatobiliary contrast agent, 20% oil‐in‐water emulsion of glyceryl‐2‐oleyl‐1,3‐di‐7‐(3‐amino‐2,4,6‐triiodophenyl)‐heptanoate (DHOG), was shown to provide superior long‐lasting visualization in microCT imaging studies, especially of the liver 10, 11, 12, 13, 14…”

mentioning

confidence: 99%

MicroCT for high‐resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice

Ohta¹,

Lai²,

Morris

et al. 2006

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Successful outcomes for patients with cancer often depend on the early detection of tumor and the prompt initiation of active therapy. Despite major advances in the treatment of many cancers, early-stage lesions often go undetected due to the suboptimal resolution of current anatomical and functional imaging modalities. This limitation also applies to preclinical animal tumor models that are crucial for the evaluation and development of new therapeutic approaches to cancer. We report a new mouse model of metastatic pheochromocytoma, generated using tail vein injection of the mouse pheochromocytoma cell (MPC) line that reproducibly generated multiple liver tumors in the animals. Furthermore, we show that in vivo microCT imaging enhanced using a hepatobiliary-specific contrast agent, glyceryl-2-oleyl-1,3-di-7-(3-amino-2,4,6-triiodophenyl)-heptanoate (DHOG), detected tumors as small as 0.35 mm as early as 4 weeks after the injection of the tumor cells. This model may be useful for in vivo studies of tumor biology and for development of new strategies to treat metastatic pheochromocytoma. ' 2006 Wiley-Liss, Inc.

show abstract

“…There has been very little work in the discovery of new x-ray contrast agents since the advent of the low and non-ionic iodine-based agents of 20 years ago. The challenge, to which a few chemists are rising, is to develop agents of sufficient contrast, low toxicity, and targeted behavior [5,6]. Since the gadolinium ion contained in many magnetic resonance (MR) contrast agents is of high enough atomic weight to act as a CT contrast agent, it is possible that, in some situations in which the MR agent is sufficiently concentrated, CT also could be used to image the agent.…”

Section: What the Physical Principles Will Allow Currently And Absolmentioning

confidence: 99%

The Future of Medical Imaging in the Detection of Early Markers of Disease

Croft

2004

Disease Markers

View full text Add to dashboard Cite

Imaging techniques are a combination of a contrast mechanism, exogenous or endogenous, and an instrument to exploit that contrast. This final chapter of these two special issues of this journal points to possible ways to improve the ability of imaging systems to exploit markers of cancer in the early detection of that disease. The aim not only is to find cancer at an earlier, more treatable stage, but to determine whether the disease discovered is dangerous and to indicate the possibilities for successful treatment. These topics are explored for each imaging system, with an emphasis on directions for future improvements.

show abstract

Imaging Efficacy of a Hepatocyte-Selective Polyiodinated Triglyceride (DHOG-LE) for Contrast–enhanced CT

Cited by 5 publications

References 17 publications

In‐vivo high‐resolution X‐ray microtomography for liver and spleen tumor assessment in mice

In‐vivo high‐resolution X‐ray microtomography for liver and spleen tumor assessment in mice

MicroCT for high‐resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice

The Future of Medical Imaging in the Detection of Early Markers of Disease

Contact Info

Product

Resources

About